Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Pharmakologie (14 Abbildungen)
Übersicht


Zum ersten Bild Abb. 3: Telmisartan - Röntgenstruktur Abb. 4: Angiotensin-I-Rezeptor Abb. 5: Plasma-Halbwertzeit Aktuelles Bild - Abb. 6: Angiotensin-I-Rezeptorblocker - Verteilungsvolumina Abb. 7: Telmisartan - PPAR-Gamma Abb. 8: SBD - DBD Abb. 9: Normaldosierung Zum letzten Bild
Abbildung 6: Angiotensin-I-Rezeptorblocker - Verteilungsvolumina
Telmisartan also has the largest volume of distribution of any ARB.1 A large volume of distribution signifies that telmisartan penetrates the tissue compartment, ensuring that local as well as systemic RAAS is blocked. Because the AT1 receptor has pathological effects that include cell hypertrophy and fibrosis, blocking AT1 at the tissue level may help to reduce target-organ damage. 1. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–499.
 
Angiotensin-I-Rezeptorblocker - Verteilungsvolumina
Vorheriges Bild Nächstes Bild   


Abbildung 6: Angiotensin-I-Rezeptorblocker - Verteilungsvolumina
Telmisartan also has the largest volume of distribution of any ARB.1 A large volume of distribution signifies that telmisartan penetrates the tissue compartment, ensuring that local as well as systemic RAAS is blocked. Because the AT1 receptor has pathological effects that include cell hypertrophy and fibrosis, blocking AT1 at the tissue level may help to reduce target-organ damage. 1. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–499.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung